REGN

Regeneron Pharmaceuticals

D
REGN
USD
21.77
(1.9115%)
Market Open
4,346.00
Volume
44.6215
EPS
-
Div Yield
30.721
P/E
127,907,328,689.28
Market Cap
Today
1.8887%
1 Week
1.667%
1 Month
-1.715%
6 Months
20.854%
12 Months
40.748%
Year To Date
32.008%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
AMGN
AMGN
3.34
(1.0032%)
USD
B
BIIB
4.09
(2.07%)
USD
GILD
GILD
0.48
(0.5721%)
USD
I
INCY
1.07
(1.6419%)
USD
I
ILMN
4.66
(3.5573%)
USD
VRTX
VRTX
4.92
(1.0381%)
USD
ABBV
ABBV
0.55
(0.2851%)
USD
BMY
BMY
-0.38
(-0.764%)
USD
LLY
LLY
0.75
(0.0829%)
USD

Title:
Regeneron Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Regeneron Pharmaceuticals Inc. is an integrated biotechnology firm. The company was founded in 1988 and is headquartered in Tarrytown, New York. It develops, manufactures and sells medicines for serious conditions such as eye diseases, allergy and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and more. Its product line includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST and ZALTRAP. The company was founded by Alfred G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988.
Do you need help or have a question?
Contact Us